BW Gestao de Investimentos Ltda. Acquires New Shares in Medline $MDLN

BW Gestao de Investimentos Ltda. acquired a new stake in Medline (NASDAQ:MDLN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 150,000 shares of the company’s stock, valued at approximately $6,300,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in MDLN. Sound Income Strategies LLC bought a new stake in shares of Medline in the fourth quarter valued at about $25,000. Entrust Financial LLC bought a new position in Medline in the fourth quarter worth about $26,000. NBC Securities Inc. bought a new position in Medline in the fourth quarter worth about $28,000. Global Retirement Partners LLC bought a new position in Medline in the fourth quarter worth about $31,000. Finally, North Star Investment Management Corp. bought a new position in Medline in the fourth quarter worth about $36,000.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Wells Fargo & Company boosted their target price on shares of Medline from $42.00 to $47.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Weiss Ratings downgraded shares of Medline from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 15th. BNP Paribas Exane reduced their target price on shares of Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. UBS Group boosted their target price on shares of Medline from $48.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Medline from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Medline has a consensus rating of “Moderate Buy” and an average price target of $50.65.

Medline Stock Performance

Shares of MDLN stock opened at $33.19 on Wednesday. Medline has a fifty-two week low of $32.83 and a fifty-two week high of $50.88. The business’s 50-day simple moving average is $42.14.

Medline (NASDAQ:MDLN) last issued its earnings results on Wednesday, May 6th. The company reported $0.33 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.04. The firm had revenue of $7.35 billion during the quarter. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. Sell-side analysts predict that Medline will post 1.5 EPS for the current year.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.